January 29, 2019 7:47am

As we climb a wall of worry, confidence and conviction are vulnerable; do we play “pick-up-stocks” – I’m leery?

Pre-open indications: 1 BUY and 3 trades

News: Neurocrine Biosciences (NBIX) and Voyager Therapeutics (VYGR) formed a strategic collaboration focused on the development and commercialization of VYGR’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two (2) programs to be determined. This collaboration combines NBIX’ expertise in neuroscience, drug development and commercialization with VYGR’s innovative gene therapy programs targeting severe neurological diseases. VYGR has a positive +$3.14 or +39.30% pre-market indication – BUY

 

I answer one question, in which company should investors put, keep and commit their money!

 

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.

 

U.S. stock index futures have a mixed picture

Dow futures are UP +0.11% (+27 points) and NASDAQ futures are DOWN -0.02% (-2 points)

 

U.S. stock index futures pointed to a lower open on Tuesday morning as investors monitored global trade developments and looked ahead to earnings releases from companies like Apple <CNBC>;

Europe markets rally ahead of key Brexit vote;

Asia markets mostly decline amid renewed US-China tensions

Data docket: consumer confidence numbers out at 10 a.m. ET as well as fourth-quarter housing vacancies. The Dallas Fed services numbers will be out at 10.30 a.m. ET. The Federal Reserve is due to start its two-day meeting Tuesday with a decision on interest rates due Wednesday.

 

Tuesday’s indications:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating

The SPDR S&P Biotech ETF (XBI) is NOT indicating

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating

The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.1% DOWNSIDE

 

Henry’omics:

Investors need to HOLD to see which way the sector will trade!

After a steep decline, there is usually an upside for the oversold however; the sector is on the road for a short-term and volatile drive!

The largest game-changer at this juncture, is IF the Federal Reserve decides to back off from its hawkish stance and abandon efforts to normalize its balance sheet.

 

Monday’s evening post, “retracement is more than a temporary reversal; Monday was just “a bridge too far” after Friday and Thursday’s positive closes.”

Last night’s percentage (%) indicators:  weak

  • Ranged of the 6 upside was +0.22% (QURE) to +10.15% (KOOL +$0.033) while the 37 downside ranged from -0.31% (CLLS) to -8.81% (NTLA) with 2 flat close (OSIR and RENE.L).

Volume stat:  extremely low

  • 10 out of the 37 upside had higher (than the 3 month average) volume
  • 1 out of the 4 downside experienced greater volume (than the 3 month average) volume

Running the month:

  • In 19 sessions in January – there was 11 positive closes, 1 holiday and 7 negative closes – so far!

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Voyager Therapeutics (VYGR) closed down -$0.41 to $8.04 this a.m. a strategic collaboration was announced focusing on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience, drug development and commercialization with Voyager’s innovative gene therapy programs targeting severe neurological diseases. There is a positive +$3.14 or +39.30% pre-market indication – BUY;

CRISPRS Therapeutics (CRSP) closed down -$2.03 to $31.17 following Friday’s +$0.91 to $33.20 after Thursday’s +$0.89 to $32.29. Wednesday’s -$1.68 to $31.40 and last Tuesday’s -$4.05 to $33.0-8 – TRADE;

Editas Medicine (EDIT) closed down-$0.80 to $20.66 after Friday’s +$0.13 to $21.46, Thursday’s +$1.23 to $21.33, Wednesday’s -$0.85 to $20.10 and last Tuesday’s -$5.19 to $20.95– TRADE;

Intellia Therapeutics (NTLA) closed down -$1.30 to $13.46 following Friday’s +$0.38 to $14.76 after Thursday’s +$0.60 to $14.38, Wednesday’s -$0.38 to $13.68 and last Tuesday’s -$1.04 to $14.16 – TRADE;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.